Gauravi Mishra
Overview
Explore the profile of Gauravi Mishra including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
470
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Malvi S, Esmy P, Muwonge R, Joshi S, Poli U, Lucas E, et al.
J Natl Cancer Inst Monogr
. 2024 Nov;
2024(67):317-328.
PMID: 39529521
Background: While recommending a human papillomavirus (HPV) single-dose vaccination schedule in 2022, the World Health Organization highlighted the need for long-term follow-up studies to monitor waning of protection. We report...
2.
Rahman M, Rahman M, Islam M, Gilmour S, Haruyama R, Budukh A, et al.
J Epidemiol
. 2024 Sep;
35(3):129-140.
PMID: 39245580
Background: The burden of cancer in India has been rising, yet testing for early detection remains low. This study explored inequalities in the uptake of breast cancer (BC) examination and...
3.
Bhatla N, Muwonge R, Malvi S, Joshi S, Poli U, Lucas E, et al.
Hum Vaccin Immunother
. 2023 Dec;
19(3):2289242.
PMID: 38078840
Long-term follow-up of a cohort of unmarried girls who received one, two, or three doses of quadrivalent HPV vaccine, between 10 and 18 years of age, in an Indian multi-centric...
4.
Vahabi M, Shahil-Feroz A, Lofters A, Wong J, Prakash V, Pimple S, et al.
Healthcare (Basel)
. 2023 Dec;
11(23).
PMID: 38063647
According to the Center for Disease Control and Prevention's National Breast and Cervical Cancer Early Detection Program, the cervical cancer screening rate dropped by 84% soon after the declaration of...
5.
Vahabi M, Mishra G, Pimple S, Wong J, Khan M, Prakash V, et al.
BMC Public Health
. 2023 Apr;
23(1):671.
PMID: 37041530
Background: While cervical cancer deaths have declined steeply in high-income countries due to the widespread use of the Papanicolaou test (Pap test), the same trend has not emerged in low...
6.
Ranganathan P, Tandon S, Khan S, Sharma P, Sharma S, Mishra G, et al.
J Cancer Policy
. 2023 Feb;
36:100412.
PMID: 36805892
Aim: Healthcare workers (HCWs) have reported negative social experiences during the COVID-19 pandemic; however, this data is largely from medical personnel. We examined living conditions, social determinants, and experiences during...
7.
Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination
Joshi S, Anantharaman D, Muwonge R, Bhatla N, Panicker G, Butt J, et al.
Vaccine
. 2022 Nov;
41(1):236-245.
PMID: 36446654
Background: The recent World Health Organization recommendation supporting single-dose of HPV vaccine will significantly reduce programmatic cost, mitigate the supply shortage, and simplify logistics, thus allowing more low- and middle-income...
8.
Vahabi M, Lofters A, Mishra G, Pimple S, Wong J
JMIR Res Protoc
. 2022 Sep;
11(9):e35093.
PMID: 36074549
Background: Human papillomavirus (HPV) is the primary cause of cervical cancer, which is preventable through screening and early treatment. The Papanicolaou (Pap) test and visual inspection with acetic acid (VIA),...
9.
Pimple S, Mishra G
Cytojournal
. 2022 May;
19:21.
PMID: 35510109
Cervical cancer remains a major public health problem, ranking as the fourth most common cause of cancer incidence and mortality in women worldwide. Wide variations in cervical cancer incidence and...
10.
Basu P, Malvi S, Joshi S, Bhatla N, Muwonge R, Lucas E, et al.
Lancet Oncol
. 2021 Oct;
22(11):1518-1529.
PMID: 34634254
Background: A randomised trial designed to compare three and two doses of quadrivalent human papillomavirus (HPV) vaccine in adolescent girls in India was converted to a cohort study after suspension...